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Background: Exosomes have great potential in regenerative medicine through the 
transfer of their bioactive cargos, such as RNA. tRF RNA and tiRNA are tRNA-
derived non-coding RNA. Here, we sought to identify the tRF/tiRNA profile in human 
mesenchymal stem cell (hMSC) exosomes. Methods: Bone marrow hMSCs were 
cultured with/without osteogenic differentiation medium and exosomes were 
harvested. RNA was extracted from: 1) control cells (Cell-NT); 2) control exosomes 
(EXO-NT); 3) differentiated cells (Cell-OM); 4) exosomes produced by differentiated 
cells (EXO-OM). RNA was sequenced to profile the small RNA with a focus on 
tRF/tiRNA. Results: tRF/tiRNA was highly enriched in hMSC exosomes. Less 
diversity was seen in the tRF/tiRNA profile in exosomes than that in parent cells. 
Selective tRF/tiRNA were packed into MSC exosomes and their profile is dependent 
on the cell maturation status. Conclusions: Our results suggest that tRF/tiRNA may 
play a role in mediating the function of exosomes in tissue regeneration. 
 
Keywords: Mesenchymal Stem Cell, Exosome, Regeneration, tRNA 
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Introduction 
Periodontal Disease 
Periodontal disease is one of the most prevalent inflammatory diseases, affecting an 
estimated 47 percent of the American population.1 It is characterized by a chronic, 
persistent immune response to a dysbiotic periodontal biofilm that results in 
destruction of the hard and soft tissue surrounding teeth.2 Factors including genetics, 
and environmental and acquired disease modifiers affect the pathogenesis of 
periodontitis.3 
 
Figure 1: Pathogenesis of Periodontitis 
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The clinical manifestations of periodontitis are due to a complex relationship between 
the disease modifiers and the microbial challenge.3 The disease presents as the 
inflammation of the supporting periodontal tissue around teeth resulting in deep 
periodontal probing depths, attachment loss and suppuration which can lead to tooth 
mobility and future tooth loss. Microbiological models proposed by Haijishengalis 
suggest the involvement of keystone pathogens, or specific microorganisms, are 
associated with periodontal destruction.4 The bacteria exhibit the expression of 
diverse molecules and virulence factors, resulting in a pro-inflammatory response, 
responsible for the ultimate tissue destruction.4 This model proposes that periodontal 
inflammation is due to the transition of microbial communities from commensal to 
pathogenic.2 One of the keystone pathogens, Porphyromonas gingivalis (P.g), is 
responsible for the periodontal tissue destruction by its virulence factors such as 
lipopolysaccharides (LPS) and gingipains. The virulence factors trigger a host 
immune regulatory response including the infiltration of immune cells and the release 
of cytokines (Fig 1).4 
 
It is believed that even at low numbers, microorganisms that are commensal in 
nature can become pathogenic. This can result in the derangement of the host 
immunity.2 Interleukin-6 is a cytokine that plays a role in tissue destruction and is 
known to be produced by many cell types.5 The immense production of cytokines 
creates a substantial impact on the immune system and stimulate alveolar bone loss 
by activating osteoclastogenic pathways.6 The receptor activator of nuclear factor 
kappa B ligand (RANKL) is one of the most important cytokines in osteoclast 
differentiation. RANKL is produced by stimulated T cells and stromal cells.7 Hence, 
understanding the role of immune regulation has laid the foundation for the therapy 
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of periodontitis. 
 
Current treatment options for periodontitis include non-surgical and surgical therapy. 
The outcome of non-surgical therapy is usually limited. For patients with slight or 
moderate disease, non-surgical therapy may be adequate to prevent disease 
progression and resume periodontal health. However, in severe disease, the 
success of non-surgical therapy is usually limited. Studies show that non-surgical 
therapy such as scaling and root planning in severe cases reduces probing depths 
but residual calculus is observed, even after repeated instrumentation in deep 
pockets.8   
 
In addition to controlling the inflammation, the reconstitution of functional periodontal 
structure is another important treatment goal. The tissue healing that is usually noted 
with non-surgical therapy is new attachment or repair. New attachment is the 
restoration of the area with connective tissue and cementum, while a repaired zone 
is the establishment of a long junctional epithelium in a previously diseased site. 
Regeneration allows the complete structural and functional reconstruction of the 
affected periodontal apparatus, which is an important therapeutic endpoint for 
periodontal regenerative medicine. The goal of regenerative periodontal therapy is to 
restore the supporting apparatus around a tooth that has been lost, which includes 
the reconstitution of the periodontal ligament (PDL), cementum and bone.9  
 
Periodontal Regeneration 
Different therapeutic modalities such as guided tissue regeneration (GTR), biologics 
in the form of growth factors/peptides and stem cell therapy aim at regeneration of 
the periodontium. GTR relies on epithelial cell exclusion to allow PDL, cementum 
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and bone to regenerate at different rates.  
Adequate angiogenesis provides blood supply and mesenchymal stem cells to the 
area of injury to facilitate healing events.10 The cascade of events of guided 
regeneration prevents fibroblast and other soft tissue cells from infiltrating the site. 
Engler et al. showed that epithelial cells can regenerate at a faster rate, up to 10 
times that of the remaining periodontal tissue.11 The concept of epithelial cell 
exclusion is for the mesenchymal stem cells (MSCs) from PDL and alveolar bone to 
migrate into the defect, allowing the slower-migrating cells with osteogenic potential 
to instead repopulate the site.12 
 
Nyman et al. demonstrated guided tissue regeneration using non-resorbable 
membranes (Millipore filters).13 The study histologically illustrated the regenerative 
potential of periodontal ligament cells through repopulation of the pluripotent PDL 
cells and new cementum.13,14 Gottlow et al. further confirmed the establishment of 
new regenerated tissue using Gore-Tex membranes.15 Collagen fibers were shown 
to insert into the new cementum.15  
 
Regeneration has been shown to be dependent on the defect type and morphology. 
Cortellini et al. found 3 wall defects had the most predictable outcome with defects 
were filled up to 95% of the original depth compared to 82% for 2 wall defects and 
39% for 1 wall.16 This highlights the importance of defect morphology. The 
containment and selection of the defect will contribute to the success of treatment.  
 
Space maintaining is another fundamental principle in the success of guided tissue 
regeneration.10 Autogenous bone and different bone substitutes are space 
maintainers for tissue growth.10 Reynolds et al. showed in a systematic review that 
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improvement in clinical parameters was greater with both graft and barrier than 
barrier alone.17 Graft materials used in regenerative periodontal therapy can be 
classified into three categories based on their impacts on bone formation: 
osteogenesis, osteoinduction, osteoconduction. If living cells are present in a graft 
material, it therefore has an osteogenic effect, as bone cells will directly contribute to 
the bone formation.18 Unlike osteogenesis, osteoinduction involves the recruitment of 
immature cells and the induction of these cells to develop into preosteoblast.19 
Osteoconductive bone graft material can only serve as a scaffold for new bone 
growth by maintenance of space, and do not induce ectopic bone formation.18 
Knowledge of these mechanisms is essential for understanding the use and 
limitations of different bone graft methods for intrabony and furcation defects. 
 
Autogenous bone directly from the patient is currently the only bone graft that has all 
three features of osteogenesis, osteoinductivity and osteoconductivity. Limitations of 
autogenous bone include added operative time for harvesting the graft, graft 
resorption, donor site morbidity and limited availability in children.20 Therefore 
alternatives have been used in guided tissue regeneration, which include harvesting 
tissue from individuals of the same species (allograft), tissue from other species 
(xenograft) and synthetically produced material (alloplast).21 Unfortunately, limited 
biological activity is associated with these alternatives. Although bone 
morphogenetic proteins (BMPs) found on demineralized freeze-dried bone (DFDBA) 
provide the osteoinductive potential, many studies have shown that the 
osteoinductive potential of DFDBA has significant variance amongst different tissue 
banks and donors.20 
 
Biologics (namely those with growth factors) include platelet-derived growth factor 
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(PDGF-BB), enamel matrix derivative (EMD) and BMPs provide key cellular signals 
for bone, PDL and cementum regeneration. 22,23 These growth factors can be used in 
conjunction with bone grafts to enhance the biological activity of bone. It also 
stimulates angiogenesis that can compensate for the limitations of the bone graft. 
However, application of both biologics and bone graft make the treatment 
expensive.20 
 
Although significant success has been obtained from the use of aforementioned 
technologies in periodontal regeneration, systematic reviews of literature suggest 
that the degree of tooth –supporting tissue regeneration is still suboptimal with less 
than 50 % bone regeneration and 20% horizontal defect fill.24 Limited clinical 
outcomes are associated with the different regenerative strategies. Therefore, novel 
therapies are still needed to promote the clinical outcome.  
 
Clinical success has been obtained from the use of donor bone and soft tissue 
regimens and the application of growth factors. However, due to the limitations of 
autogenous tissue, stem cell therapy is a promising alternative. 25 
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Figure 2: Periodontal regeneration 
Cell-Mediated Therapy 
Cell therapy is being intensively investigated in animal models and clinical trials for 
the treatment of a broad range of diseases and injuries, including periodontitis. 
Increasing evidence suggests the therapeutic value of mesenchymal stem cells 
(MSCs) are derived from the wide range of bioactive molecules that they secrete, 
which exert pleiotropic effects during wound healing such as stimulating proliferation 
and differentiation, enhancing angiogenesis and modulating host immune responses. 
26,27 MSCs respond in an adaptive way to environmental stimulation by modulating 
the transcription and translation process. Injury stimulates MSCs homing and the 
release of trophic factors by interactions between the C-XC chemokine receptor 4 
(CXCR4) and stromal cell derived factor 1a.27,28 Other examples of the trophic 
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factors include Substance P, a neurotransmitter which mobilizes the CD29 stromal –
like cell, that induces accelerated wound healing and promotes repair of corneal 
injury.29 MSCs from different sources (e.g. bone marrow, adipose tissue) vary in 
differentiation potential and angiogenic ability to other cell types such as adipocyte, 
osteoblast and chondrocyte. 30 
 
Table 1. Summarizes recent human studies using MSCs for regeneration in 
dentistry. Yamada et al. reported that the localized injection of MSCs into an open 
interproximal space resulted in an improved interproximal papilla fill of 2.55mm. 
Kaigler et al. further showed a significant result in the bone density of patients who 
received engineered stem cell therapy for sinus augmentation.31,32 Results from this 
study were noted both radiographically and histologically. These studies support the 
therapeutic outcome of stem cell delivery and provide alternative treatment to 
periodontal hard and soft tissue regeneration. 
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Study n. 
Study 
Type 
Status Cell Source 
Cell 
expansion 
in Lab 
Delivery carrier Outcome 
Yamada 
et al. 17 
Case 
report Completed 
Autologous BMSC 
from iliac crest Yes 
PRP, thrombin/10% 
calcium chloride 
5.12 PD loss, 4.29 
CAL gain, 
3.12mm bone 
gain 
Feng et 
al. 3 
Case 
report Completed 
Autologous PDL 
cells from third 
molars 
Yes Synthetic bone grafting material 
No adverse 
effects during 32-
72 months. 
Chen et 
al. 35 RCT Recruiting 
Autologous PDL 
cells from third 
molars 
Yes: cell 
sheet 
technique  
N/A N/A 
Gjerde et 
al. 11 RCT Completed 
Autologous BMSC 
from iliac crest Yes 
Biphasic calcium 
phosphate granules 
No adverse effect 
and regeneration 
of bone (GBR) 
noted for implant 
placement. 
Kiagler et 
al. 24 RCT Completed 
Autologous BMSC 
from iliac crest Yes 
Tricalcium Phosphate 
scaffold 
Comparable 
results to GBR 
control group but 
better bone 
density noted in 
the stem cell 
therapy group. 
 Table 1: Clinical studies using cell therapy for periodontal regeneration.24,32,33 
However, limitations still exist in the current cell-based therapy as the treatment 
effect is usually dose dependent and a large number of MSCs will be needed to 
produce the desired effect. Mesenchymal stem cells are difficult to isolate and to 
select the optimal cell population for treatment is still under investigation.14 Additional 
equipment is needed to store the cells, making it uneconomical for dental practice. 
New therapies are currently being investigated and exosome therapy is a promising 
substitute. 
 
Exosome-mediated regenerative therapy 
Exosomes are nanoscopic lipid bilayer vesicles (~100 nm in diameter) secreted by 
most cell types.34,35 They are formed inside the multivesicular endosomes and 
released when multivesicular bodies fuse with the plasma membrane. Various 
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molecular constituents from their cell of origin are selectively packed into 
exosomes.36 They were originally believed to be a vehicle to clear proteins from 
cells; however, studies are currently investigating other functions of these 
multivesicular bodies. Instead, emerging as novel mediators in cell-cell 
communication, exosomes have been shown to be involved in various physiological 
and pathological processes including immune response, embryonic development, 
tumorigenesis, and wound healing.37 In regenerative medicine, MSC exosomes have 
been reported to promote tissue healing in different organs such as heart, lung, 
kidney, liver and brain, demonstrating a promising clinical value as a substitute of 
cell delivery based treatment.38  
 
Exosomes contain multiple protein molecules such as annexins, tetraspanins (CD63, 
CD81 and CD9), heat shock proteins and low amounts of phosphatidylserine and 
cell specific proteins, that have an evolutionarily conserved function during exosome 
biogenesis.28,39 An association exists between the molecular markers on an 
exosome and that of their parent cell; hence they may have similar properties. Like 
the mesenchymal parent cells, which have functions in tissue-repair promotion, anti-
inflammation, immunosuppression and neuroprotection, exosome mediated therapy 
has been shown to have similar therapeutic effects.40 It is still largely unknown about 
how exosomes exert their function; however, the enclosed RNA has been 
considered the major mediator for the cellular responses induced by exosomes.  
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Figure 3: tRNA fragment and exosome therapy 
Exosome based therapy has emerged as a viable alternative therapy for stem cell 
delivery.41 The advantage of exosome delivery to conditional cell therapy include the 
feature that it triggers a less immunogenic response than the parent cells and can be 
stored for up to 6 months under -20oC temperature without any alterations in the 
biological make up and activity.28 Another significant advantage is that the cargos 
inside exosomes are better protected from degradation than their parent counter-
part, which may provide a more predictable clinical outcome. 
 
The regenerative potential of MSC exosomes has been demonstrated in different 
disease models. Treating mice with myocardial ischemia /reperfusion injury, with 
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exosome based therapy from cardiosphere derived cells, showed a decrease in 
infarct size.42 An enhanced cardiac functionality, reduction in scar tissue and an 
increase in viable tissue were also seen after exosome therapy. Further study 
showed that therapeutic effects were partially mediated by the enclosed miRNAs.42 
Exosomes excreted by MSCs were found to activate pro-survival signaling by 
reducing oxidative stress, resulting in decrease tissue destruction.28  
 
The interest of applying exosomes for bone regeneration has increased over the 
years. Intravenous infusion of MSC exosomes significantly ameliorated the 
osteoporotic phenotype in systemic lupus erythematosus (SLE) mice. 43 Very 
recently, it was shown that exosomes produced by MSCs derived from induced-
pluripotent stem cells or bone marrow, enhanced bone formation in critical size 
calvarial defects.26,44,45In addition, MSC exosomes also contain other functions such 
as immune modulation, anti-oxidation, etc (Table 2).46–48 
 
 
Target organ 
 
 
Function and Role 
 
Therapeutic benefits and mechanism 
Cardiovascular disease  • Angiogenesis  
• Antifibrosis 
• Anti apoptosis 
• Anti oxidation 
• Chemo attraction 
 
 
1. Reduce infarct size 
2. Enhance tissue repair 
3. Increase angiogenesis 
 
Cutaneous wound healing  1. Increase re-epithelization. 
2. Inhibit apoptosis of skin cell 
3. Promote proliferation of skin 
cells  
 
Kidney damage 1. Tubuloepithelial regeneration 
2. Reduce tubular cell apoptosis 
3. Reduce fibrosis 
4. Reduce tubular atrophy  
 
Liver injury 1. Hepatocyte regeneration 
2. Inhibit liver fibrosis 
3. Reduce hepatocyte apoptosis 
 
Lung injury  1. Reduce lung edema  
2. Reduce inflammation 
3. Improve pulmonary 
hypertension. 
4. Improve ventricular 
hypertrophy. 
5. Improve lung vascular 
remodeling. 
 
Table 2: Application of exosome-mediated regenerative medicine.48–52 
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tRNA, tiRNA, tRF and their significance. 
Through next generation RNA sequencing, we found that significant amounts of 
transfer RNA (tRNA) exist in MSC exosomes. tRNA is an adaptor molecule that 
decodes mRNA and translates proteins. Recent studies have demonstrated that 
tRNAs are also a major source of small non-coding RNAs (ncRNAs). These tRNA-
derived ncRNAs are not random degradation products of tRNA, but rather produced 
through precise cleavages by specific nucleases. In general, tRNA-derived ncRNAs 
are classified into two main categories: tiRNA (tRNA halves) and tRF (tRNA-derived 
fragments). 
 
The biogenesis of tRF/tiRNAs is shown in Fig 6. Briefly, tRFs are generated by 
multiple cleavages of tRNA precursors or mature tRNA. These products are 
classified by their sites of origin: 1) tRF-5: these RNA are from the 5’ part of the 
mature tRNA and the cleavage occurs at the D loop; 2) tRF-3: these RNA 
correspond the 3’ parts of mature tRNAs containing 3’CCA termini and formed by the 
cleavage of the T loop; 3) i-tRF: these RNA are derived from the internal region of 
the mature tRNA and usually contain the anti-codon loop; 4) tRF-1: these RNA 
originate from the beginning of the 3’end flanking sequences with poly-U residue at 
3’end. tRFs are ~16-25 nucleotides in size and deeply conserved in nature. Little is 
known about the molecular mechanism underlying the generation of tRFs. In many 
cases, tRFs appear to be produced in a manner similar to the canonical miRNA 
pathway. However, a DICER-independent tRF production mechanism was identified 
recently.53 tiRNA is formed when the tRNA molecule is cleaved at the anticodon to 
produce 30–35 nucleotide 5′-tRNA halves and 40–50 nucleotide 3′-tRNA halves.42 
tRF molecules are smaller than the tiRNA halves and angiogenin is responsible for 
this cleavage.42 
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Figure 4: tRNA fragments 
It is believed that tRFs and tiRNA exert their biological functions as small noncoding 
RNAs. For example, they can inhibit gene expression and block protein translation in 
a similar manner as microRNA.8 They can also directly inhibit protein synthesis by 
displacing the translation initiation factor eIF4G from mRNA.42 They regulate the 
stability of protein complexes through RNA and protein interaction.42 The also play a 
role in stress response by assembling stress granules. Emerging in vivo evidence 
start to reveal the important functions of tRF/tiRNA. It has been shown that an 
acquired metabolic disorder can be transferred to offspring through the tRNA 
fragments.42 Injection of sperm tRF/tiRNA fractions from mice with metabolic 
disorders induced by a high-fat diet to normal zygotes resulted in a similar metabolic 
disorder in the F1 offspring. These results and others suggest the epigenetic nature 
of the tRNA fragments in the extracellular vesicles/exosomes and show their 
important role in a variety of physiological and pathological conditions, such as 
spermatogenesis, cancers, neurodegeneration, metabolic disorders, etc. 42  
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Because of the potential of exosomes as an alternative to stem cell therapy in 
regenerative medicine, our long-term goal is to develop an MSC exosome-
based therapy to promote periodontal regeneration. Understanding the 
components of MSC exosomes will help us better design this novel 
therapeutic technique. Cells at different maturation stages may produce 
different exosomes. In this study, our aim is to determine if MSCs produce 
exosomes with different tRNA components during osteogenic differentiation. 
Results from this study will help to develop better therapeutics for periodontal 
regeneration based on MSC exosomes.  
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Methods and Materials 
Cell Culture 
Mesenchymal stem cells of human bone marrow were ordered from RoosterBio Inc. 
(RoosterBio, MD, USA). These cells had the potential to differentiate into osteocytes, 
adipocytes and chrondrocytes. These cells were cultured in a high Performance 
Basal Medium (RoosterBio, MD, USA) supplemented with Media Booster GTX 
(RoosterBio, MD, USA) and 1% Antibiotic/Antimycotic solution (10,000 units of 
penicillin, 10,000µg of streptomycin, and 25µg of Amphotericin B per mL, HyClone, 
USA) in T175 tissue culture flasks. The cells were subpassaged at 90% confluency. 
At passage 3 medium was then aspirated and the cells were washed for 3 times with 
warm PBS to completely remove the residue of expansion medium. The hMSCs 
were then cultured in control medium (denoted as NT, DMEM supplemented with 
1g/L glucose, 10% exosome-depleted FBS and 1% Antibiotic/Antimycotic solution) or 
osteogenic medium (denoted as OM, control medium supplemented with ascorbic 
acid (50 ug/mL), dexamethasone (10-8 M) and β-glycerophosphate (5 mM)) for 4 
days. After 4 days,medium was collected. For total cell RNA experiment, cells were 
cultured in 6 well plates with/without osteogenic medium for 4 days 
 
Extraction of Exosomes  
Exosomes were isolated from the collected culture media at day 4 by sequential 
ultracentrifugation.54 Briefly, hMSCs culture media was centrifuged at 500×g for 10 
minutes, 2000×g for 10 minutes with a bench-top centrifuge (Beckman Coulter, 
USA). Then the supernatant was collected and centrifuged at 10,000×g for 30 
minutes to remove large cell organelles such as lysosomes and mitochondria, 
followed by 100,000×g for 70 minutes to concentrate the exosomes. Then the 
supernatant was discarded and the pellet was resuspended in 0.9% NaCl and 
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centrifuged at 100,000×g for 70 minutes to remove the contaminated protein from 
the medium. The resulted exosome pellet was then resuspended in 0.9% NaCl and 
stored at -80 ˚C until further use. All centrifugation was performed at 4 ˚C. 
 
Extraction of RNA 
The suspension of exosome (maximal volume=100ul) was added with 1 mL TRIzol. 
Samples were placed in -80 0C for a few minutes then thawed again and spun on a 
votex. Each sample was added with 0.2 mL of chloroform per 1mL of TRIzol sample 
and the caps of the tube were secured. The tubes were then vigorously shaken by 
hand for 15 seconds and then incubated at room temperature for 2-3 minutes. The 
sample was then centrifuged at 13,000 × rpm for 15 minutes at 4°C. 
The aqueous phase of the sample was carefully removed by pipetting the solution 
into another tube without drawing any other phase. The medium was added with 
0.5ml of 100% isopropanol to the aqueous phase, per 1 mL of TRIzol® Reagent, and 
incubated at room temperature for 10 minutes. After that, centrifugation of 13,000 × 
rpm for 15 minutes at 4°C was performed. The supernatant was then removed from 
the tube and the pellet was washed with 1 mL of 75% ethanol per 1 mL of TRIzol® 
Reagent with brief vortex. The sample then underwent centrifugation at 10,000 × g 
for 5 minutes at 4°C. The wash was then discarded. The RNA pellet was air dried for 
5–10 minutes and resuspended in the RNase-free water by passing the solution up 
and down several times through a pipette tip or vortex. 
 The RNA concentration was determined by a bioanalyzer. RNA was sent to 
Arraystar for small RNA sequencing. 
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Figure 5: Method Flowchart 
Gene Sequencing 
 
 
 
Figure 6: Gene Sequencing Work Flow Sheet 
 
hMSCs  
(NT & OM )   
Differential ultracentrifugation 
Flask, D4 
RNA extraction by TRIzol 
tRF/tiRNA profile 
(Next generation RNA 
sequencing) 
Collect supernatant;  
Exosomes;  
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Total RNA samples were first pretreated as following to remove some RNA 
modifications that interfere with small RNA-seq library construction: 3’-aminoacyl 
(charged) deacylation to 3’-OH for 3’ adaptor ligation, 3’-cP (2’, 3’-cyclic phosphate) 
removal to 3’-OH for 3’ adaptor ligation, 5’-OH (hydroxyl group) phosphorylation to 
5’-P for 5’-adaptor ligation, m1A and m3C demethylation for efficient reverse 
transcription. Then pretreated total RNA was used to prepare the sequencing library 
in the following steps: 1) 3'-adapter ligation; 2) 5'-adapter ligation; 3) cDNA 
synthesis; 4) PCR amplification; 5) size selection of 135~160 bp PCR amplified 
fragments (corresponding to 15~40 nt small RNA size range). The libraries were 
denatured as single-stranded DNA molecules, captured on Illumina flow cells, 
amplified in situ as sequencing clusters and sequenced for 50 cycles on Illumina 
NextSeq 500 system per the manufacturer’s instructions. 
 
Image analysis and base calling were performed using Solexa pipeline v1.8 (Off-Line 
Base Caller software, v1.8). Sequencing quality was examined by FastQC software 
and trimmed reads (pass Illumina quality filter, trimmed 3’-adaptor bases by 
cutadapt) were aligned to mature-tRNA and pre-tRNA sequences from GtRNAdb 
using NovoAlign software (v2.07.11). The remaining reads are aligned to the 
transcriptome sequences (mRNA/ rRNA /snRNA /snoRNA /piRNA /miRNA). The 
expression profiling and differential expression of tRFs & tiRNAs & known miRNAs 
were calculated based on normalized TPM. Hierarchical clustering, scatter plots and 
volcano plots were performed with the differentially expressed tRFs & tiRNAs in R or 
Python environment for statistical computing and graphics.  
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Results 
In Fig 7, electrophoresis in the bioanalyzer allowed the RNA to be visualized 
accordingly to the nucleotide length. The exosome groups illustrate a greater 
concentration of fragment RNA located in the nucleotide length below 200, while a 
greater diversity was seen in the cell groups which included patterns that resemble 
28S, 18S,5S ribosomal RNA.  
 
RNA was sent to Arraystar Inc. for library preparation and sequencing. Quality score 
(Q-score) is a prediction of the probability of an error in base calling during 
sequencing. For example, Q30 stands for one in every 1000 base calls that is 
predicted to be incorrect. O20 means one base call is incorrect in every 100 
sequenced bases. Q30 is considered a benchmark for quality in next generation 
sequencing. Fig.8 shows that all 4 groups show a high (>92%) and comparable Q30, 
indicating that the quality of our sequencing was high. 
 
After data analysis, we found that the exosome and cell groups display distinct 
profile in terms of ratio of tRNA and miRNA. In the exosome, a large portion of the 
reads were aligned to the tRNA fragments, while in the cell groups, a larger portion 
were assigned to the micro-RNA as seen in Fig 9. Additionally, the length distribution 
in Fig.10 highlights the variation in nucleotide reads. The cell groups have a variable 
distribution in the nucleotide length while the exosome groups show a peak between 
30-to 37-nucleotide. This is comparable to the length of tRNA fragments, indicating a 
greater expression of tRNA fragments in exosomes compared to the cell groups.  
Very interestingly, a dramatic difference was seen in the tRNA fragment species 
when the cells were compared to exosomes, regardless of their differentiation 
status(Fig 11-14). In the total cell RNA, the tRNA fragments were derived from a 
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wide range of tRNAs carrying different anti-codons, however the majority of the 
exosomal tRF/tiRNAs were from a limited number of parent tRNAs. Furthermore, 
more diverse tRNA fragments (tRF-5, tRF-3, tRF-1, i-tRF and tRNA halves) were 
found in cellular RNA. In exosomes, most of the tRNA fragments were tiRNA-5. Our 
data suggest that RNA in exosome is not a simple copy of cytosol RNA and only 
specific tRF/tiRNAs may be selectively packaged into the exosomes. 
 
We also investigated whether the cell maturation status will impact the constituents 
of their exosomal tRF/tiRNA. We found that, the difference between two sample 
types (cell vs exosome) was much more dramatic than the difference between two 
different maturation stages (NT vs OM). However, some of the tRF/tiRNA were found 
differentially expressed between the non-differentiated and differentiated samples 
(Table 3 &4). 
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Discussion 
Exosome-based therapy has many advantages to current stem cell treatment. For 
example, exosomes are more resilient to degradation and can be stored for a longer 
time frame in proper conditions.28 Emerging animal studies and early human clinical 
trials have demonstrated the safety and efficacy of exosome therapy.48 For example, 
the injection of exosomes from cardiosphere cells (stem cells) decreased the 
ischemic area in experimental myocardial infarction models. Exosome therapy can 
ameliorate neurological disorders and promote healing through stimulating a 
multitude of pathways and associated with angiogenesis, cell proliferation and 
inflammation.43 Preliminary results from our laboratory also suggested that exosome 
therapy is a potential substitute for stem cell delivery in bone regeneration. 
Therefore, to determine the active biological components in MSC exosomes, will 
have great value in understanding the therapeutic effects on exosome therapy. 
 
This study elaborates the difference in tRF/tiRNA gene expression between the 
exosome groups and the parent cell groups. A large number of RNA in exosomes is 
mapped to tRF/tiRNA, which has not been reported before. Emerging evidence 
suggests the important functions of small tRNA fragments in development and 
diseases. For example, metabolic disorder can be transferred from parent to 
offspring by the tRNA fragments in the vesicles of sperm.55 Significant difference 
was found in the tRF/tiRNA species between the exosomes and the parent cells, 
suggesting that RNA in exosome is not a simple copy of the cytosolic RNA and a 
selective mechanism is used to pack the tRF/tiRNA into exosomes. This is 
consistent with the observation in other exosomal RNA including microRNA.56,57 
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Interestingly, the presence of selective tRNA species may also be associated with 
the maturation status of stem cells. Although a smaller difference was seen between 
samples at two maturation stages when compared to that between exosomes and 
cells, a few tRF/tiRNA were found differentially expressed between the non-
differentiated and differentiated samples. This is only the first step in appreciating the 
intricacy of these small tRNA fragments. In the future, more studies are needed to 
further determine the function of these differentially expressed tRF/tiRNA in MSCs. 
 
Several limitations existed in our current study. We only sequenced one sample in 
each group. Studies with a larger n value would be required to assess if the 
differences and similarities are consistent across the different groups. It would also 
be interesting to see if there would be a greater difference when cells are treated for 
a longer period of time (> 4 days) with an osteogenic medium. A longer treatment 
may induce a more dramatic phenotypic change in MSC cells and exosomes, which 
therefore can impact the tRF/tiRNA component. Due to the technical limitations, the 
purity of our exosome may also be a concern.  A standard sequential 
ultracentrifugation protocol was used in our study to isolate exosomes, however, 
some large protein complexes may still remain in the pellets. The purity of the 
exosome samples could be improved if a gradient ultracentrifugation is applied to 
further eliminate the proteins for RNA analysis.  
 
So far, the mechanism of how the tRF/tiRNA are packed into the exosome is still 
unclear. The packaging process of exosomes seem selective, otherwise we would 
expect to see similar diversity in the tRF/tiRNA in the exosomes compared to that in 
the parent cells, highlighting that most tRF/tiRNA are tiRNA-5. In future, it will be 
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interesting to investigate if this selective packaging process is related to specific 
tRF/tiRNA structure.  
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Conclusion 
This study showed that: 1) small RNA was highly enriched in MSC exosomes; 2) A 
significant larger portion of MSC exosome RNA was identified as tRF/tiRNA when 
compared to that in parent cells; 3) to our surprise, less diversity was seen in the 
tRF/tiRNA in exosomes compared to that of total cell RNA, suggesting a selective 
mechanism may be involved in transporting the tRF/tiRNA into exosomes; 4) some 
of the tRF/tiRNA were found differentially expressed between the non-differentiated 
and differentiated samples. The exact functions of exosomal tRF/tiRNA are still to be 
determined but understanding the basic make-up of the exosome RNA will provide 
valuable insight to modulating the function of exosomes for future periodontal 
regenerative medicine. 
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Figures 
 
Figure 7: Bioanalyzer result illustrating the presence of RNA. 
Sample 
Name 
Number of 
Reads 
Number of Reads (Quality 
Score>=30) 
Q30 
Percen
t (%) 
Exo_D4_NT 10616651 9931551 93.5 
Cell_D4_NT 7749172 7195321 92.9 
Exo_D4_OM 8891861 8188074 92.1 
Cell_D4_OM 9696944 9085004 93.7 
Figure 8: Quality Score. The percentage of bases with Q>30 should be greater than 80% 
 
 
D4-NT D4-OM 
[nt] 
28S rRNA 
18S rRNA 
Small RNA 
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Figure 9: Summary of the mapping results of aligned reads by sample. Each sample consists 
of reads that can be classified into: mapped to pre-miRNA and mapped to tRF & tiRNA 
 
 
Figure 10: Length distribution of the 4 different groups 
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Figure 11: The tRF/tiRNA gene expressing level in the Cell NT group 
 	  
	  
Figure 12: The tRF/tiRNA gene expressing level in Cell OM group 
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Gene sequence 
Cell NT 
Gene sequence 
Cell OM 
Small fragment 
tRNA species 
Cell NT 
Small fragment 
tRNA species 
Cell OM 
Val-AAC Val-AAC tRF-5 
ti-RNA-5 
tRF-5 
i-tRF 
ti-RNA 5 
Gln-CTG Gln-CTG tRF-5 
i-tRF 
ti-RNA-5 
tRF-3 
tRF-5 
i-tRF 
ti-RNA-5 
 
Ser-TGA Ser-TGA tRF-3 
tRF-5 
tRF-3 
Gln-TTG Gln-TTG i-tRF 
ti-RNA 5 
ti-RNA i 
tRF-3 
 
i-tRF 
ti-RNA 5 
ti-RNA i 
Leu -CAG Leu -CAG tRF-3 
i-tRF 
ti-RNA 5 
tRF-5  
 
tRF-3 
i-tRF 
ti-RNA 5 
 
Leu-AAG Leu-AAG i-tRF 
i-tRF 3 
 
i-tRF 
i-tRF 3 
i-tRF 5 
Leu-TAG Leu-TAG 
 
 
i-tRF 
i-tRF 3 
 
i-tRF 
i-tRF 3 
i-tRF 5 
 
Lys-TTT Lys-TTT ti-RNA 5 
ti-RNA 3 
 
ti-RNA 5 
 
Ser-AGA Ser-AGA tRF-3 
tRF-5 
 
tRF-3 
 
Table 3: tRF/tiRNA differentially expressed between Cell NT and Cell OM groups. 
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Figure 13: The tRF/tiRNA gene expressing level in the Exo NT group 	  
	  	  
Figure 14: The tRF/tiRNA gene expressing level in the Exo OM group 
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Table 4: tRF/tiRNA differentially expressed between Exo NT and Exo OM groups. 
 
 	  	  	  	  	  	  
 
 	    
Gene sequence 
Exo NT 
Gene sequence 
Exo OM 
Small fragment 
tRNA species 
Exo NT 
Small fragment 
tRNA species 
Exo OM 
Lys-TTT Lys-TTT tiRNA-5 - 
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